Befunolol is a beta blocker introduced in 1983 by Kakenyaku Kakko. It is currently in experimental status, and is being tested for the management of open angle glaucoma.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Methimazole | The excretion of Befunolol can be decreased when combined with Methimazole. |
| Escitalopram | The serum concentration of Befunolol can be increased when it is combined with Escitalopram. |
| Dronedarone | The metabolism of Befunolol can be decreased when combined with Dronedarone. |
| Lasmiditan | Lasmiditan may increase the bradycardic activities of Befunolol. |
| Givosiran | The serum concentration of Befunolol can be increased when it is combined with Givosiran. |
| Verapamil | The risk or severity of adverse effects can be increased when Verapamil is combined with Befunolol. |
| Ranolazine | The serum concentration of Befunolol can be increased when it is combined with Ranolazine. |
| Formoterol | Befunolol may increase the sympathomimetic activities of Formoterol. |
| Haloperidol | The serum concentration of Befunolol can be increased when it is combined with Haloperidol. |
| Fluoxetine | The serum concentration of Befunolol can be increased when it is combined with Fluoxetine. |
| Octreotide | The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Befunolol. |
| Ponesimod | The risk or severity of bradycardia can be increased when Ponesimod is combined with Befunolol. |
| Estetrol | The risk or severity of hyperkalemia can be increased when Befunolol is combined with Estetrol. |
| Fexinidazole | The risk or severity of adverse effects can be increased when Befunolol is combined with Fexinidazole. |
| Viloxazine | The metabolism of Befunolol can be decreased when combined with Viloxazine. |
| Imatinib | The serum concentration of Befunolol can be increased when it is combined with Imatinib. |
| Clozapine | The serum concentration of Befunolol can be increased when it is combined with Clozapine. |
| Clobazam | The serum concentration of Befunolol can be increased when it is combined with Clobazam. |
| Vilanterol | The therapeutic efficacy of Vilanterol can be decreased when used in combination with Befunolol. |
| Fedratinib | The serum concentration of Befunolol can be increased when it is combined with Fedratinib. |
| Spironolactone | The risk or severity of hyperkalemia can be increased when Befunolol is combined with Spironolactone. |
| Desvenlafaxine | The serum concentration of Befunolol can be increased when it is combined with Desvenlafaxine. |
| Etrasimod | The risk or severity of bradycardia can be increased when Etrasimod is combined with Befunolol. |
| Lacosamide | The risk or severity of ventricular arrhythmias, bradycardia, and heart block can be increased when Befunolol is combined with Lacosamide. |